Crispr Therapeutics Viking Therapeutics: 2026 Stock Showdown
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Evaluating the value of travel points against cash back can impact your rewards strategy. Discover which option offers the greatest benefits for your needs.
26,201 articlesAs biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
LNG demand is primed to rise dramatically as the world leans on cleaner fuels. This guide highlights why the trend ma...
A modest insider sale can spark questions, but the bigger signal for investors is a company delivering solid earnings...
Oklo has zigzagged from a peak near $193 to much lower levels, raising questions about its momentum and prospects. Th...
Paramount has emerged as the apparent victor in a months-long bidding war to buy Warner Bros. Discovery’s film and TV...
Nvidia dominates today’s AI data centers, but the real threat to its throne may be a risk that sits in plain sight. T...
Lyft delivers a dual narrative after Q4 2025: growing bookings and riders on one hand, while a sharp stock decline an...
Three clear visions for AMD in 2026, from AI-driven demand to capital returns. Learn what could move the stock and ho...
Investors are weighing Brookfield Corp after their latest earnings. This guide breaks down what the earnings signal m...
A clear, practical breakdown of DEFT's Q4 2025 results and what the deft 2025 earnings transcript signals for 2026. L...
DraftKings fights for growth across shifting state rules and expanding iGaming. This article breaks down what to watc...
Berkshire Hathaway is positioned to become a much larger Alphabet holder as the tech giant pursues a bold AI financin...